论文部分内容阅读
目的探讨纤溶酶治疗糖尿病性合并急性脑梗塞的疗效及其安全性。方法 98例糖尿病性脑梗塞患者,随机分成两组:治疗组和对照组,治疗组应用注射用纤溶酶100U加入250ml的0.9%氯化钠注射液中静滴;对照组则给予疏血通注射液6ml加入250ml的0.9%氯化钠注射液中静滴,用法均1次/日,连用2周,其余治疗相同。评价治疗前和治疗后2周的神经功能缺损以及临床疗效,观察不良反应,检测治疗前后血液纤维蛋白原(Fb)含量并进行比较。结果治疗后治疗组疗效显著优于对照组(P<0.05),纤维蛋白原(Fb)水平具有显著差异(P<0.05)。结论注射用纤溶酶对急性糖尿病性脑梗塞的近期疗效显著,能明显降低患者血液纤维蛋白原(Fb)含量,且无明显副作用。
Objective To investigate the efficacy and safety of plasmin in the treatment of diabetic patients complicated with acute cerebral infarction. Methods A total of 98 diabetic patients with cerebral infarction were randomly divided into two groups: treatment group and control group. In the treatment group, 100U of plasmin was injected intravenously into 250ml of 0.9% sodium chloride injection. In the control group, Injection 6ml added 250ml of 0.9% sodium chloride injection intravenously, usage are 1 / day, once every 2 weeks, the remaining treatment the same. Evaluation of neurological deficits before and 2 weeks after treatment and clinical efficacy, adverse reactions were observed before and after treatment of blood fibrinogen (Fb) content and compared. Results After treatment, the therapeutic effect of the treatment group was significantly better than that of the control group (P <0.05), and the fibrinogen (Fb) level was significantly different (P <0.05). Conclusions Fibrinolytic enzyme for injection has obvious curative effect on acute diabetic cerebral infarction in recent years, and can obviously reduce the content of blood fibrinogen (Fb) in patients with no obvious side effects.